Cyclic Peptides as Aggregation Inhibitors for Sickle Cell Disease

J Med Chem. 2023 Dec 14;66(23):16062-16074. doi: 10.1021/acs.jmedchem.3c01484. Epub 2023 Nov 21.

Abstract

Sickle cell disease is a missense genetic disorder characterized by the aggregation of deoxy-HbS into helical fibers that distort erythrocytes into a sickle-like shape. Herein, we investigate, through molecular dynamics, the effect of nine 5-mer cyclic peptides (CPs), tailor-designed to block key lateral contacts of the fibers. Our results show that the CPs bind orthogonally to the main HbS pocket involved in the latter contacts, with some revealing exceedingly long residence times. These CPs display moderate to high specificity, exhibiting molecular recognition events even at a HbS/CP (1:1) ratio. A much lower HbS-CP binding free energy, longer residence times, and higher specificity are also found relative to a previously reported CP with modest in vitro antisickling activity. These results indicate that some of these CPs have the potential to reduce the concentration of aggregation-competent deoxy-HbS, precluding or delaying the formation of lateral contact at the homogeneous nucleation stage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia, Sickle Cell* / drug therapy
  • Entropy
  • Erythrocytes / metabolism
  • Hemoglobin, Sickle*
  • Humans
  • Molecular Dynamics Simulation

Substances

  • Hemoglobin, Sickle